| Year |
Citation |
Score |
| 2022 |
Keszler P, Maloni H, Miles Z, Jin S, Wallin M. Telemedicine and Multiple Sclerosis: A Survey of Health Care Providers Before and During the COVID-19 Pandemic. International Journal of Ms Care. 24: 266-270. PMID 36545646 DOI: 10.7224/1537-2073.2021-103 |
0.502 |
|
| 2022 |
Roth EG, Minden SL, Maloni HW, Miles ZJ, Wallin MT. A Qualitative, Multiperspective Inquiry of Multiple Sclerosis Telemedicine in the United States. International Journal of Ms Care. 24: 275-281. PMID 36545645 DOI: 10.7224/1537-2073.2021-117 |
0.46 |
|
| 2020 |
Mukharesh L, Maloni H, Maiberger M, Chen W, Wallin M. Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis. Clinical Neurology and Neurosurgery. 195: 105886. PMID 32470781 DOI: 10.1016/J.Clineuro.2020.105886 |
0.54 |
|
| 2020 |
Wallin MT, Whitham R, Maloni H, Jin S, Duckart J, Haselkorn J, Culpepper WJ. The Multiple Sclerosis Surveillance Registry: A Novel Interactive Database Within the Veterans Health Administration. Federal Practitioner : For the Health Care Professionals of the Va, Dod, and Phs. 37: S18-S23. PMID 32341633 |
0.473 |
|
| 2019 |
Yeroushalmi S, Maloni H, Costello K, Wallin MT. Telemedicine and Multiple Sclerosis: A Comprehensive Literature Review. Journal of Telemedicine and Telecare. 1357633X19840097. PMID 31042118 DOI: 10.1177/1357633X19840097 |
0.444 |
|
| 2018 |
Maloni H. Cognitive Impairment in Multiple Sclerosis The Journal For Nurse Practitioners. 14: 172-177. DOI: 10.1016/J.NURPRA.2017.11.018 |
0.429 |
|
| 2017 |
Wallin MT, Culpepper WJ, Maloni H, Kurtzke JF. The Gulf War era multiple sclerosis cohort: 3. Early clinical features. Acta Neurologica Scandinavica. 137: 76-84. PMID 28832890 DOI: 10.1111/ane.12810 |
0.423 |
|
| 2015 |
Wininger M, Craelius W, Settle J, Robinson S, Isaac B, Maloni H, Moradi M, Newby NA, Wallin M. Biomechanical analysis of spasticity treatment in patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders. 8: 203-11. PMID 26668586 DOI: 10.1177/1756285615601390 |
0.621 |
|
| 2015 |
Settle JR, Maloni HW, Bedra M, Finkelstein J, Zhan M, Wallin MT. Monitoring medication adherence in multiple sclerosis using a novel web-based tool: A pilot study. Journal of Telemedicine and Telecare. PMID 26253748 DOI: 10.1177/1357633X15597115 |
0.623 |
|
| 2015 |
Maloni HW, Wallin MT. Presentation of multiple sclerosis with comorbid Huntington's disease. Clinical Neurology and Neurosurgery. 136: 86-8. PMID 26079261 DOI: 10.1016/J.Clineuro.2015.05.006 |
0.532 |
|
| 2015 |
Settle JR, Robinson SA, Kane R, Maloni HW, Wallin MT. Remote cognitive assessments for patients with multiple sclerosis: a feasibility study. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 1072-9. PMID 25583842 DOI: 10.1177/1352458514559296 |
0.626 |
|
| 2014 |
Wallin MT, Kurtzke JF, Culpepper WJ, Coffman P, Maloni H, Haselkorn JK, Mahan CM. Multiple sclerosis in gulf war era veterans. 2. Military deployment and risk of multiple sclerosis in the first gulf war. Neuroepidemiology. 42: 226-34. PMID 24862835 DOI: 10.1159/000360701 |
0.42 |
|
| 2013 |
Turner AP, Wallin MT, Sloan A, Maloni H, Kane R, Martz L, Haselkorn JK. Clinical management of multiple sclerosis through home telehealth monitoring: results of a pilot project. International Journal of Ms Care. 15: 8-14. PMID 24453757 DOI: 10.7224/1537-2073.2012-012 |
0.525 |
|
| 2013 |
Maloni HW. Multiple sclerosis: Managing patients in primary care Nurse Practitioner. 38: 24-35. PMID 23454903 DOI: 10.1097/01.NPR.0000427606.09444.c6 |
0.402 |
|
| 2012 |
Wallin MT, Culpepper WJ, Coffman P, Pulaski S, Maloni H, Mahan CM, Haselkorn JK, Kurtzke JF. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain : a Journal of Neurology. 135: 1778-85. PMID 22628389 DOI: 10.1093/Brain/Aws099 |
0.351 |
|
| 2012 |
Royal W, Lee-Wilk T, Wallin M, Bever C, Kane R, Maloni H, Finkelstein J, Cha E, McCarthy M, Levin M, Tyor W, Culpepper J, Mitchell L, Zhan M. CXCR3+ Naive T Helper Cell Percentages Correlate with Neuropsychological Test Abnormalities in Patients with MS (P04.102) Neurology. 78: P04.102-P04.102. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.102 |
0.483 |
|
| 2002 |
Calabresi PA, Austin H, Racke MK, Goodman A, Choyke P, Maloni H, McFarland HF. Impaired renal function in progressive multiple sclerosis. Neurology. 59: 1799-801. PMID 12473777 DOI: 10.1212/01.Wnl.0000036618.68674.7A |
0.443 |
|
| 2000 |
Maloni HW. Pain in multiple sclerosis: an overview of its nature and management The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. 32. PMID 2000137876 |
0.336 |
|
| 1998 |
Calabresi PA, Fields NS, Maloni HW, Hanham A, Carlino J, Moore J, Levin MC, Dhib-Jalbut S, Tranquill LR, Austin H, McFarland HF, Racke MK. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology. 51: 289-92. PMID 9674825 DOI: 10.1212/Wnl.51.1.289 |
0.416 |
|
| 1997 |
Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, Calabresi PA, Brennan MB, Maloni HW, McFarland HF, Lin HC, Patnaik M, Jacobson S. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Medicine. 3: 1394-7. PMID 9396611 DOI: 10.1038/Nm1297-1394 |
0.4 |
|
| 1997 |
Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology. 49: 1111-6. PMID 9339698 DOI: 10.1212/Wnl.49.4.1111 |
0.389 |
|
| 1997 |
Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H, McFarland HF. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology. 49: 862-9. PMID 9305355 DOI: 10.1212/Wnl.49.3.862 |
0.323 |
|
| 1997 |
Tresley RM, Stone LA, Fields N, Maloni H, McFarland H, Frank JA. Clinical safety of serial monthly administrations of gadopentetate dimeglumine in patients with multiple sclerosis: implications for natural history and early-phase treatment trials. Neurology. 48: 832-5. PMID 9109864 DOI: 10.1212/Wnl.48.4.832 |
0.341 |
|
| 1996 |
McFarland HF, Stone LA, Calabresi PA, Maloni H, Bash CN, Frank JA. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Multiple Sclerosis (Houndmills, Basingstoke, England). 2: 198-205. PMID 9345374 DOI: 10.1177/135245859600200406 |
0.48 |
|
| 1995 |
Stone LA, Smith ME, Albert PS, Bash CN, Maloni H, Frank JA, McFarland HF. Blood-brain barrier disruption on contrast-enhanced mri in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age Neurology. 45: 1122-1126. PMID 7783875 DOI: 10.1212/Wnl.45.6.1122 |
0.451 |
|
| 1995 |
Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, McFarland HF. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis Annals of Neurology. 37: 611-619. PMID 7755356 DOI: 10.1002/Ana.410370511 |
0.403 |
|
| 1994 |
Frank JA, Stone LA, Smith ME, Albert PS, Maloni H, McFarland HF. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: Implications for treatment trials Annals of Neurology. 36: S86-S90. PMID 8017894 DOI: 10.1002/Ana.410360719 |
0.327 |
|
| 1992 |
McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis Annals of Neurology. 32: 758-766. PMID 1471866 DOI: 10.1002/Ana.410320609 |
0.351 |
|
| Show low-probability matches. |